Adaptimmune Therapeutics plc's NY-ESO SPEAR T-cell therapy showed "promising efficacy and acceptable safety" in a pilot study of multiple myeloma patients.
Investigators observed overall response rates of 76% at 100 days and 44% at one year, with a median response duration of at least 12 months and a median predicted overall survival of about 3 years.
No fatal adverse events were reported, with the most common adverse events being generally expected in the patient population.
The company said a follow-up study combining the NY-ESO SPEAR T-cell therapy with Keytruda will transition to GlaxoSmithKline plc, which recently acquired the rights to the program.
